Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 2,689-2,700 of 4,306
Drug study icon
CompletedNCT00861796

CYR-101 in people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Toul
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
France
Sponsor
Cyrenaic Pharmaceuticals
Condition
Schizophrenia
Behavioral study icon
CompletedNCT03751280

Efficacy of PEAR-004 in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Garden Grove
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralFrom 18 Years to 65 Years
Countries
United States
Sponsor
Novartis Pharmaceuticals
Condition
Schizophrenia
Drug study icon
CompletedNCT01716975

EVP-6124 (Alpha-7 nAChR) for schizophrenia

This study is completed in the United States, in Australia, in the United Kingdom, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.

Multiple locations, including Phoenixville
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United States, Australia, United Kingdom, ...
Sponsor
FORUM Pharmaceuticals Inc
Condition
Schizophrenia
Drug study icon
CompletedNCT00149292

LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Moscow
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
Russia
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
Device study icon
CompletedNCT03064776

m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Budapest
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDeviceA study involving a tool, app, wearable, test, or medical device.From 18 Years to 45 Years
Countries
Hungary, Israel, Spain
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Condition
Schizophrenia
Drug study icon
CompletedNCT01515423

Paliperidone Palmitate 3 Month and 1 Month Formulations for people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 70 Years
Countries
United States, Australia, France, ...
Sponsor
Janssen Research & Development, LLC
Condition
Schizophrenia
Drug study icon
CompletedNCT00103727

Talnetant Versus Placebo And Risperidone In Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
GlaxoSmithKline
Condition
Schizophrenia
Other study type icon
CompletedNCT02897167

the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients

This summary needs review. Please check the official study record and contact the research team for details.

In Santander
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaObservationalA study where researchers collect information without assigning a treatment.From 15 Years to 50 Years
Countries
Spain
Sponsor
Fundación Marques de Valdecilla
Condition
Schizophrenia
Drug study icon
CompletedNCT01396421

the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Canada, Japan, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT00455650

the Effects of Mecamylamine and Varenicline in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Boston
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 68 Years
Countries
United States
Sponsor
Massachusetts General Hospital
Condition
Schizophrenia
Drug study icon
CompletedNCT01377233

Safety study of once Weekly Zicronapine in schizophrenia

This study is completed in the United States. It is testing once Weekly Zicronapine for schizophrenia.

Multiple locations, including Garden Grove
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.